Roivant Sciences (NASDAQ:ROIV) CEO Sells 200,000 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of the company’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $28.24, for a total value of $5,648,000.00. Following the completion of the sale, the chief executive officer owned 1,647,546 shares of the company’s stock, valued at $46,526,699.04. This represents a 10.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Eric Venker also recently made the following trade(s):

• On Friday, February 13th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $26.49, for a total value of $5,298,000.00.
• On Monday, January 12th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $21.92, for a total value of $4,384,000.00.
• On Wednesday, December 24th, Eric Venker sold 75,000 shares of Roivant Sciences stock. The shares were sold at an average price of $22.53, for a total transaction of $1,689,750.00.
• On Tuesday, December 23rd, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $22.45, for a total transaction of $4,490,000.00.

Roivant Sciences Stock Performance

NASDAQ:ROIV remained flat at $27.80 during trading hours on Thursday. 4,008,171 shares of the company’s stock traded hands, compared to its average volume of 5,681,042. The firm has a 50 day moving average price of $25.80 and a 200 day moving average price of $21.08. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $30.33.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. TD Cowen reiterated a “buy” rating on shares of Roivant Sciences in a report on Wednesday, March 4th. Weiss Ratings downgraded Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, February 9th. HC Wainwright lifted their price objective on Roivant Sciences from $33.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Guggenheim boosted their price objective on Roivant Sciences from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Finally, Leerink Partners raised their target price on shares of Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $28.81.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Morgan Stanley raised its position in Roivant Sciences by 31.7% in the 4th quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock valued at $1,266,402,000 after buying an additional 14,036,696 shares during the last quarter. Vanguard Group Inc. boosted its position in Roivant Sciences by 8.4% during the 4th quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company’s stock worth $912,681,000 after acquiring an additional 3,254,113 shares during the last quarter. Rubric Capital Management LP grew its stake in shares of Roivant Sciences by 14.7% during the 2nd quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock worth $229,574,000 after acquiring an additional 2,603,260 shares in the last quarter. State Street Corp grew its stake in shares of Roivant Sciences by 4.8% during the 2nd quarter. State Street Corp now owns 19,773,480 shares of the company’s stock worth $222,847,000 after acquiring an additional 911,827 shares in the last quarter. Finally, UBS Group AG raised its holdings in shares of Roivant Sciences by 570.0% in the fourth quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock valued at $399,080,000 after purchasing an additional 15,645,836 shares during the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.